Astrazeneca Pharma India Ltd. Share Price

AstraZeneca Pharma India Limited :i demand notice

Company has informed t te exchange inconnection with the demand notice dated July 27, 2026 (‘Demand Notice’) issued by the National Pharmaceutical Pricing Authority (‘NPPA’) for alleged overcharging under the Drugs (Prices Control) Order, 2013 with respect to Betaloc-50 (Metoprolol 50 mg tablets). The Hon'ble High Court of Delhi, vide its order dated August 24, 2026, has stayed the operation of the aforesaid Demand Notice until the next date of hearing i.e. February 10, 2027, subject to the Company depositing 15% of the amount mentioned in the Demand Notice with the Registrar General of the Court. Further, please find the details as required under the SEBI Circular HO/49/14/14(7)2025- CFD-POD2/I/3762/2026 dated January 30, 2026 attached herewith as Annexure .

AstraZeneca Pharma India maintains growth momentum with a strong start to FY2026–27

Pre Market Report & Global Cues| 11 Aug

Global cues are slightly weak. US markets closed a bit lower. Nothing major, but US 10Y yield has moved up to ~4.7%. More important, crude jumped to $88 after a sharp move yesterday. That’s something to watch. Asian markets are mixed. Japan and Singapore are positive, while China and Taiwan are a bit weak. Gift Nifty is flat, so no clear direction at open. Rupee: around 95.3, still on the weaker side. Stocks in focus: Positive: • BSE - getting added to Nifty 50 • Gland Pharma - strong results (~47% profit growth) • Zen Tech - ₹295 Cr defence order • Lupin - USFDA approval • BEL - ₹541 Cr order win • M&M - good production & sales numbers Weak: • Wipro - moving out of Nifty 50 • Vodafone Idea - big loss (~₹3,700 Cr) • Zee - weak profit • Inox Wind, AstraZeneca Pharma - weak numbers • Keystone Realtors - lower pre-sales Also watch: Zydus Life, MRF, RVNL, Siemens, Bata, NBCC (results today) Important: CPI inflation data tomorrow after market hours. Crude and US yields are the main pressure points for now. Market may open flat and then move based on stock-specific action.

UK Expands Fast-Track Visa Programme to Boost Innovation and Attract Global Talent

The UK government has expanded its Global Talent Visa programme to include more than 100 companies, allowing businesses such as AstraZeneca and Jaguar Land Rover to recruit highly skilled professionals through a faster and more flexible immigration process. Previously available only to universities and research institutions, the programme is now being extended to support innovation-led companies and strengthen the country's research and technology ecosystem. The move comes as the UK seeks to attract global talent amid tighter immigration policies in the US. The Global Talent Visa costs £766 and applications are typically processed within three weeks, while successful applicants can bring their partners and children and become eligible for indefinite leave to remain after 3 to 5 years. The government has also announced support measures, including reimbursement of visa fees for fast-growing companies and a dedicated concierge service for overseas recruitment. In addition, the Future Technology Research and Innovation scheme will be expanded, enabling more businesses to host researchers, scientists, interns and technical specialists for up to 2 years. The policy also addresses concerns over high immigration costs, with some UK visa applicants previously paying more than £10,000 (around $13,461) in various fees, while the US is considering increasing the application fee for skilled worker H-1B visas to $100,000. Overall, these initiatives reflect the UK's strategy to enhance its competitiveness by making it easier for global talent and research-driven businesses to establish and expand their presence in the country.

India's Defence Sector Remains in Focus Amid Rising Government Orders

India's defence sector continues to attract investor attention as the government's focus on indigenous manufacturing and higher capital expenditure strengthens growth prospects for domestic defence companies. Over the past few months, the Ministry of Defence has awarded several contracts to Indian manufacturers under the 'Make in India'initiative, boosting order books across the sector. Companies involved in defence equipment, electronics, missiles, warships, and aerospace are expected to benefit from sustained government spending. A healthy order pipeline improves revenue visibility, supports long-term earnings growth, and enhances business stability. Investors are also optimistic about increasing defence exports, which have reached record levels in recent years. The sector remains one of the key long-term themes for the Indian market, supported by policy reforms, import substitution, and modernization of the armed forces. While short-term price movements may remain volatile, companies with strong execution capabilities and robust order books are likely to remain in focus. Learning Outcome: When analyzing defence companies, investors should look beyond quarterly profits and evaluate order book size, execution capability, export opportunities, and government policy support. A strong order book often indicates stable future revenue and long-term growth potential.

AstraZeneca Pharma India Expands Breast Cancer Treatment Portfolio with Fresh CDSCO Approval

AstraZeneca Pharma India has received approval from the Central Drugs Standard Control Organisation (CDSCO) to import and distribute Trastuzumab Deruxtecan (Enhertu) 100mg/5ml lyophilized powder for concentrate for solution for infusion for an additional indication in breast cancer treatment, further expanding its oncology portfolio in India. This follows the approval granted in June, which allowed Enhertu, in combination with pertuzumab, to be used as a first-line treatment for adult patients with unresectable or metastatic HER2-positive breast cancer. Enhertu is an antibody-drug conjugate designed to treat specific HER2-expressing cancers, and the latest approval broadens its approved use in the Indian market, subject to applicable statutory requirements. On the financial front, AstraZeneca Pharma India reported mixed Q4 performance, with net profit declining 23% year-on-year to ₹44.8 crore from ₹58.2 crore, while revenue increased 20.4% to ₹578.6 crore from ₹480.4 crore. EBITDA fell 29.4% to ₹60.9 crore from ₹86.2 crore, and the EBITDA margin narrowed to 10.5% from 17.9% in the corresponding period last year. The latest regulatory approval reflects the company's continued focus on expanding access to advanced cancer therapies while strengthening its presence in the oncology segment.